# EDGAR Filing Document

**Accession Number:** 0001761055
**File Stem:** 0001193125-26-064158
**Filing Date:** 2026-2
**Character Count:** 2788
**Document Hash:** 3828d9ff1aea0bcceaafad6d0fc6a948
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-064158.hdr.sgml**: 20260223

**ACCESSION NUMBER**: 0001193125-26-064158

**CONFORMED SUBMISSION TYPE**: 497

**PUBLIC DOCUMENT COUNT**: 11

**FILED AS OF DATE**: 20260223

**DATE AS OF CHANGE**: 20260223

**EFFECTIVENESS DATE**: 20260223

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BlackRock ETF Trust
- **CENTRAL INDEX KEY:** 0001761055

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0731

**FILING VALUES:**
- **FORM TYPE:** 497
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-228832
- **FILM NUMBER:** 26665890

**BUSINESS ADDRESS:**
- **STREET 1:** 100 BELLEVUE PARKWAY
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19809
- **BUSINESS PHONE:** 8004417762

**MAIL ADDRESS:**
- **STREET 1:** 100 BELLEVUE PARKWAY
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19809

## Series and Classes Contracts Data

### iShares Health Innovation Active ETF (Series ID: S000069260)

---

|  |  |
|:---|:---|
| Class Name                           | Class ID   |
| iShares Health Innovation Active ETF | C000221226 |

---

## Series and Classes Contracts Data

### iShares Health Innovation Active ETF (Series ID: S000069260)

| Class ID   | Class Name                           | Ticker Symbol   |
|:---|:---|:---|
| C000221226 | iShares Health Innovation Active ETF |  |

?xml version='1.0' encoding='ASCII'? iShares Health Innovation Active ETF - SUPP

------

#### BlackRock ETF Trust
iShares Health Innovation Active ETF

(the "Fund")

#### Supplement dated February 23, 2026 to the Summary Prospectus and the

#### Prospectus of the Fund, each dated November 28, 2025, as amended or supplemented to date

#### Effective February 24, 2026, the following changes are made to the Fund's Summary Prospectus and Prospectus, as applicable:

#### The section of the Summary Prospectus and the Prospectus entitled "Summary of Principal Risks" is amended to add the following:
**Focus Risk.** Under normal circumstances, the Fund focuses its investments in the securities of a limited number of issuers. This may subject the Fund to greater issuer-specific risk and potential losses than a fund that invests in the securities of a greater number of issuers.

#### The section of the Prospectus entitled "More Information About the Fund — A Further Discussion of Principal Risks" is amended to add the following:
**Focus Risk**. Under normal circumstances, the Fund focuses its investments in the securities of a limited number of issuers. This may subject the Fund to greater issuer-specific risk and potential losses than a fund that invests in the securities of a greater number of issuers.

#### Shareholders should retain this Supplement for future reference.
PR2-BMED-0226SUP